After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...